Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy

In a placebo-controlled trial, we examined the efficacy of a 6-month ("extended") transdermal nicotine therapy vs. the 8-week ("standard") therapy in 471 Caucasian smokers with either normal or reduced rates of nicotine metabolism as determined at pretreatment. Extended therapy w...

Full description

Saved in:
Bibliographic Details
Published inClinical pharmacology and therapeutics Vol. 87; no. 5; p. 553
Main Authors Lerman, C, Jepson, C, Wileyto, E P, Patterson, F, Schnoll, R, Mroziewicz, M, Benowitz, N, Tyndale, R F
Format Journal Article
LanguageEnglish
Published United States 01.05.2010
Subjects
Administration, Cutaneous
Adult
Aryl Hydrocarbon Hydroxylases - genetics
Aryl Hydrocarbon Hydroxylases - metabolism
Cohort Studies
Cytochrome P-450 CYP2A6
Delayed-Action Preparations - administration & dosage
Delayed-Action Preparations - metabolism
Drug Administration Schedule
Female
Follow-Up Studies
Genetic Variation - genetics
Humans
Longitudinal Studies
Male
Middle Aged
Nicotine - administration & dosage
Nicotine - metabolism
Nicotine - therapeutic use
Predictive Value of Tests
Smoking - drug therapy
Smoking - genetics
Smoking - metabolism
Smoking Cessation - methods
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:In a placebo-controlled trial, we examined the efficacy of a 6-month ("extended") transdermal nicotine therapy vs. the 8-week ("standard") therapy in 471 Caucasian smokers with either normal or reduced rates of nicotine metabolism as determined at pretreatment. Extended therapy was superior to standard therapy in genotypic or phenotypic reduced metabolizers (RMs) of nicotine but not in normal metabolizers (NMs). RMs of nicotine are candidates for extended transdermal nicotine therapy, whereas an alternative therapeutic approach may be needed for those with normal rates of nicotine metabolism.
ISSN:1532-6535
DOI:10.1038/clpt.2010.3